Merck & Co., Inc.: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 3, 2023 and accepted by EDGAR at Nov 3, 2023, 16:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-01 to 2023-09-30 | $15.96bn | us-gaap:Revenues |
| Revenue | 9 months2023-01-01 to 2023-09-30 | $45.48bn | us-gaap:Revenues |
| Cost of revenue | 3 months2023-07-01 to 2023-09-30 | $4.26bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2023-01-01 to 2023-09-30 | $12.21bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2023-07-01 to 2023-09-30 | $3.31bn | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-01-01 to 2023-09-30 | $20.90bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-07-01 to 2023-09-30 | $2.52bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2023-01-01 to 2023-09-30 | $7.70bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2023-07-01 to 2023-09-30 | $317.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2023-01-01 to 2023-09-30 | $836.0m | us-gaap:InterestExpense |
| Income tax | 3 months2023-07-01 to 2023-09-30 | $870.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-01-01 to 2023-09-30 | $2.33bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-01 to 2023-09-30 | $4.75bn | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-01-01 to 2023-09-30 | $1.59bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-01 to 2023-09-30 | $1.86 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-01-01 to 2023-09-30 | $0.62 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-01 to 2023-09-30 | $1.87 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-01-01 to 2023-09-30 | $0.63 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-01 to 2023-09-30 | 2,546,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-01-01 to 2023-09-30 | 2,549,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-01-01 to 2023-09-30 | $12.76bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-01-01 to 2023-09-30 | $2.87bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2023-01-01 to 2023-09-30 | $5.59bn | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2023-01-01 to 2023-09-30 | $953.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-09-30 | $8.61bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $31.95bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $106.73bn | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $23.09bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2023-09-30 | $33.97bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-09-30 | $887.0m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2023-09-30 | $41.25bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-036717. Last ingested by Listed: Oct 29, 2026, 06:44 ET. Listed shows no prices and gives no investment advice.